Sanyog Pharma Consultants (Indore) Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 M
- Revenue Growth 13.80%
- Profit Growth 30.51%
- Ebitda -71.03%
- Net Worth 56.02%
- Total Assets 11.65%
About Sanyog Pharma Consultants (Indore)
Sanyog Pharma Consultants (Indore) Private Limited (SPCIPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 June 2013 and has a history of 11 years and eight months. Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 M.
Ashok Peethambaran and Sunita Tanvade serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U73100MP2013PTC030947
-
Company No.
030947
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Jun 2013
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Sanyog Pharma Consultants (Indore)?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashok Peethambaran
|
Director | 13-Jun-2013 | Current |
|
Sunita Tanvade
|
Director | 10-Feb-2014 | Current |
Financial Performance of Sanyog Pharma Consultants (Indore).
Sanyog Pharma Consultants (Indore) Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 13.8% increase. The company also saw a substantial improvement in profitability, with a 30.51% increase in profit. The company's net worth Soared by an impressive increase of 56.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sanyog Pharma Consultants (Indore)?
In 2017, Sanyog Pharma Consultants (Indore) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Sep 2018 | Others | ₹2.00 M | Open |
How Many Employees Work at Sanyog Pharma Consultants (Indore)?
Unlock and access historical data on people associated with Sanyog Pharma Consultants (Indore), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sanyog Pharma Consultants (Indore), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sanyog Pharma Consultants (Indore)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
